Flunazine®
(flunixin meglumine paste)
Equine Paste

CAUTION: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION
Each 30-g syringe of Flunazine Equine Paste contains flunixin meglumine equivalent to 1500 mg flunixin.

INDICATIONS
Flunazine Equine Paste is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse.

ACTIVITY
Flunixin meglumine is a potent, nonnarcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine as an analgesic in the rat yeast paw test. Oral studies in the horse show onset of flunixin activity occurs within 2 hours of administration. Peak response occurs between 12 and 16 hours and duration of activity is 24 to 36 hours.

CONTRAINDICATIONS
There are no known contraindications to this drug when used as directed.

WARNING
Do not use in horses intended for human consumption.

PRECAUTIONS
The effect of flunixin meglumine on pregnancy has not been determined. Studies to date show there is no detrimental effect on stallion spermatogenesis with or following the recommended dose of flunixin meglumine.

SIDE EFFECTS
During field studies with flunixin meglumine, no significant side effects were reported.

To report suspected adverse drug events, for technical assistance or to obtain a copy of the Safety Data Sheet (SDS), contact Bimeda, Inc. at 1-888-524-6332. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VET or online at www.fda.gov/reportanimalae.

DOSAGE AND ADMINISTRATION
The recommended dose of flunixin is 0.5 mg per lb of body weight once daily. The Flunazine Equine Paste syringe, calibrated in twelve 250-lb weight increments, delivers 125 mg of flunixin for each 250 lbs (see dosage table). One syringe will treat a 1000-lb horse once daily for 3 days, or three 1000-lb horses one time.

DOSAGE TABLE			
Syringe Mark*	**Horse Weight (lbs)**	**Flunazine Equine Paste Delivered (g)**	**mg flunixin Delivered**
0	---	---	---
250	250	2.5	125
500	500	5.0	250
750	750	7.5	375
1000	1000	1.0	500

* Use dial edge nearest syringe barrel to mark dose.

The paste is orally administered by inserting the nozzle of the syringe through the interdental space, and depositing the required amount of paste on the back of the tongue by depressing the plunger.

Treatment may be given initially by intravenous or intramuscular injection of Flunazine Injectable Solution, followed by Flunazine Equine Paste on Days 2 to 5. Flunixin meglumine treatment should not exceed 5 consecutive days.

TOXICITY
No toxic effects were observed in rats given oral flunixin meglumine 2 mg/kg per day for 42 days. Higher doses produced ulceration of the gastrointestinal tract. The emetic dose in dogs is between 150 and 250 mg/kg. Flunixin was well tolerated in monkeys dosed daily with 4 mg/kg for 56 days. No adverse effects occurred in horses dosed orally with 1.0 or 1.5 mg/lb for 5 consecutive days.

Rev. 03/22 M-23-0477

Flunazine®
(flunixin meglumine paste)
Equine Paste

STORAGE
Store at 20°C - 25°C (68°F - 77°F), excursions permitted between 15°C - 30°C (between 59°F - 86°F).

Approved by FDA under ANADA # 200-581

List Number	Unit Size	Case Size
1FLU015	30 g	48 (4 x 12)

MANUFACTURED FOR:
Bimeda, Inc.
Le Sueur, MN 56058
www.bimeda.com

N.A. CORP. ADDRESS:
Bimeda, Inc.
One Tower Lane
Oakbrook Terrace, IL 61081

For further information and queries, contact Bimeda at (888) 524-6332 or US-info@Bimeda.com

Rev. 03/22 M-23-0477